BioAge Labs, Inc.
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
BIOA$5.78+1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Unaudited Conde nsed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2025 | 2024 | |
| OPERATING ACTIVITIES | ||
| Net loss | $(12,928) | $(12,992) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 2,949 | 852 |
| Depreciation expense | 37 | 33 |
| Loss on extinguishment of debt | — | 250 |
| Non-cash interest expense | 117 | 876 |
| Non-cash lease expense | 53 | 1 |
| (Gain) loss from changes in fair value on warrants | (59) | 8 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (361) | — |
| Prepaid expenses and other current assets | (1,180) | (937) |
| Other assets | 1 | — |
| Accounts payable | 2,047 | 361 |
| Accrued expenses and other current liabilities | (6,949) | (4,124) |
| Deferred revenue | (1,090) | — |
| Net cash used in operating activities | (17,363) | (15,672) |
| INVESTING ACTIVITIES | ||
| Purchase of property and equipment | (426) | — |
| Purchases of marketable securities | (77,562) | — |
| Net cash used in investing activities | (77,988) | — |
| FINANCING ACTIVITIES | ||
| Proceeds from Series D issuance | — | 170,000 |
| Issuance costs paid on Series D issuance | — | (502) |
| Term loan principal payments | (1,500) | (1,500) |
| Proceeds from issuance of common shares upon stock option exercises | — | 3 |
| Net cash (used in) provided by financing activities | (1,500) | 168,001 |
| Effect of changes in exchange rate on cash, cash equivalents, and restricted cash | (12) | 19 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (96,863) | 152,348 |
| Cash, cash equivalents and restricted cash at beginning of period | 354,349 | 24,957 |
| Cash, cash equivalents and restricted cash at end of period | $257,486 | $177,305 |
| Supplemental non-cash disclosure: | ||
| Unpaid Series D issuance costs included in accounts payable and accrued expenses | $— | $256 |
| Purchases of property and equipment in accounts payable and accrued expenses | $73 | $— |
| Cash paid for interest | $217 | $427 |
| Right-of-use assets obtained in exchange for lease obligation | $3,106 | $282 |
| Cash, cash equivalents, and restricted cash reconciliation | ||
| Cash and cash equivalents | $257,486 | $173,992 |
| Restricted cash | — | 3,313 |
| Cash, cash equivalents, and restricted cash ending balance | $257,486 | $177,305 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.